ReviewNature reviews. Microbiology2007
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
Review in Nature reviews. Microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Consequences of Shigella infection in young children: a systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012.Epidemiology and infection · 2015Pooled it
- The Shigella human challenge model.Epidemiology and infection · 2013Pooled it
- A phase I trial of WRSS1, aHuman vaccines & immunotherapeutics · 2019Trial
- Trial
- Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.Clinical and vaccine immunology : CVI · 2016Trial
- Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.Clinical and vaccine immunology : CVI · 2016Trial
- Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Clinical and vaccine immunology : CVI · 2016Trial
- Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.Clinical immunology (Orlando, Fla.) · 2011Trial
- Review
- Expanded prevalence of group 4 capsule expression and its genetic requirements in a broad array ofmSphere · 2026Article
- Global distribution and genomic characteristics ofInfectious medicine · 2026Article
- Protective immunity againstmSphere · 2026Article
- Robust performance of culture, real-time PCR, and genomic approaches for shigella serotyping in a pediatric surveillance cohort.PLoS neglected tropical diseases · 2026Article
- Development of a NovelVaccines · 2026Article
- Robust Performance of Culture, qPCR, and Genomic Approaches for Shigella Serotyping in a Pediatric Surveillance Cohort.medRxiv : the preprint server for health sciences · 2026Article
- Disrupting the vicious cycle of malnutrition and enteropathy: advancing strategies to improve child physical and neurocognitive outcomes.Frontiers in public health · 2026Review
- TheeLife · 2025Article
- Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibitMicrobiology spectrum · 2025Article
- An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs.The American journal of tropical medicine and hygiene · 2025Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
More than 50 years of research has yielded numerous Shigella vaccine candidates that have exemplified both the promise of vaccine-induced prevention of shigellosis and the impediments to developing a safe and effective vaccine for widespread use, a goal that has yet to be attained. This Review discusses the most advanced strategies for Shigella vaccine development, the immune responses that are elicited following disease or vaccination, the factors that have accelerated or impeded Shigella vaccine development and our ideas for the way forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.